Philips stock steadies as restructuring and consent decree costs weigh on earnings

Philips stock trades against a complex backdrop of restructuring, litigation and operational recovery after the Dutch health technology group Koninklijke Philips N.V. (ISIN NL0000009538) reported weaker earnings for Q2 2024 while reiterating its transformation plan across Diagnostics & Image-Guided Therapy and Connected Care.

Earnings pressured by consent decree costs

According to the companys Q2 2024 financial reporting, Philips generated comparable sales of approximately EUR 4.1 billion in Q2 2024, which management described as broadly flat versus the prior year quarter as growth in image-guided therapy and monitoring offset softer demand in certain diagnosis systems and personal health categories.

Philips reported an adjusted EBITA of around EUR 390 million in Q2 2024, reflecting an adjusted EBITA margin near 9.5 percent, compared with a margin of roughly 10.3 percent in Q2 2023 as additional costs linked to the ongoing consent decree and remediation activities weighed on profitability despite continued savings from its productivity program.

Net income attributable to shareholders turned lower in Q2 2024, with Philips posting a profit of roughly EUR 120 million compared with about EUR 150 million in Q2 2023, as restructuring charges and legal-related expenses more than offset a modest improvement in financial income and lower transaction costs versus the prior year period.

Full year 2024 guidance and margin focus

For fiscal 2024, Philips confirmed that it continues to target low- to mid-single digit comparable sales growth for the group, supported by an order book in its health systems businesses that the company has indicated remained at a healthy level at the end of Q2 2024 and is expected to convert into revenue over the coming quarters.

The group reiterated its ambition to expand the adjusted EBITA margin into a low teens percentage for full year 2025 and to further improve profitability thereafter, with management highlighting ongoing cost savings from its multi-year restructuring program that is designed to remove structural expenses and improve the effectiveness of operations across manufacturing, R&D and overhead functions.

Philips also reported that free cash flow generation improved versus the prior year, with operating cash flow for Q2 2024 reaching a positive triple-digit million euro figure driven by tighter working capital management and lower outflows related to prior-year restructuring and separation activities, providing additional flexibility to support investments and meet the financial obligations arising from the consent decree framework.

Product portfolio anchored in image-guided therapy

Philips derives a significant part of its health systems revenue from advanced diagnostic imaging and image-guided therapy solutions, including systems used in minimally invasive procedures in cardiology, oncology and peripheral vascular care, where the company emphasizes a focus on integrating hardware, software and services into comprehensive clinical workflows.

The Diagnostics & Image-Guided Therapy segment continued to contribute a substantial share of group revenue in Q2 2024, with management pointing to mid-single digit comparable sales growth in that segment driven by strong demand for image-guided therapy systems and related services, partially offset by more cautious purchasing patterns for large capital equipment in some markets.

Philips stock and market context

Philips shares are listed on Euronext Amsterdam and the New York Stock Exchange via NYSE-listed American Depositary Shares, providing global investors with access to the companys equity as it continues to navigate restructuring, regulatory commitments and its strategy to drive growth in health technology.